secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001104659-23-032774
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist reports Q4 net loss $0.69/shr, cash $237M; positive Ph2b JNJ-2113 and rusfertide REVIVE data
--------------------------------------------------------------------------------

- Net loss per share Q4 2022: $0.69 ($34.2M) vs $0.77 ($36.9M) in Q4 2021; full year 2022 net loss $127.4M.
- Cash, cash equivalents and marketable securities $237.4M at Dec 31, 2022; expected to fund operations through end of 2024.
- Phase 2b FRONTIER 1 study of JNJ-2113 in psoriasis met primary endpoint: statistically significant PASI-75 at Week 16 across all doses, well tolerated.
- Phase 2 REVIVE study of rusfertide in polycythemia vera met primary endpoint: proportion of responders on rusfertide vs placebo p=0.0003; 92.3% phlebotomy-free.
- License revenue from Janssen collaboration declined to zero in Q4 2022 as performance obligations completed June 2022; total milestones and royalties potential $855M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/tm239503d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-032774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer